Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
GAZYVA vs OCREVUS ZUNOVO
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Obinutuzumab is a type II anti-CD20 monoclonal antibody that binds to the CD20 antigen on B cells, inducing direct cell death, antibody-dependent cellular cytotoxicity, and antibody-dependent cellular phagocytosis.
OCREVUS ZUNOVO is a recombinant humanized monoclonal antibody that targets CD20-positive B cells. It binds to the CD20 antigen on the surface of pre-B and mature B lymphocytes, leading to antibody-dependent cellular cytotoxicity and complement-mediated lysis, resulting in B-cell depletion.
Chronic lymphocytic leukemia (CLL) in combination with chlorambucil,Follicular lymphoma (FL) in combination with bendamustine followed by obinutuzumab monotherapy for patients with relapsed or refractory FL,Previously untreated follicular lymphoma in combination with chemotherapy
FDA: Treatment of relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.,FDA: Treatment of primary progressive multiple sclerosis (PPMS).
100 mg intravenously on day 1, 8, 15 of cycle 1, then 100 mg on day 1 of subsequent 28-day cycles for 6 cycles total.
Initial dose: 300 mg intravenous infusion over 4 hours followed 2 weeks later by a second 300 mg intravenous infusion over 4 hours. Subsequent doses: 600 mg intravenous infusion over 3.5 hours every 6 months.
The terminal elimination half-life is approximately 28 days (range 14-42 days) following the last dose, supporting a 6-month dosing interval for maintenance therapy.
Terminal elimination half-life is approximately 26 days (range 20–30 days). This long half-life supports every-6-month dosing. Multiple doses lead to steady-state by 24 weeks.
Obinutuzumab is a monoclonal antibody expected to be degraded into small peptides and amino acids via catabolic pathways, similar to endogenous immunoglobulins; not metabolized by CYP450 enzymes.
Ocrevus Zunovo is a monoclonal antibody that is degraded into small peptides and amino acids via general protein catabolism. No specific metabolic pathways or enzymes are involved.
Obinutuzumab is eliminated primarily through intracellular catabolism, with no significant renal or biliary excretion. <1% of the dose is excreted unchanged in urine.
Ocrelizumab is metabolized via catabolism into small peptides and amino acids; no specific excretion studies have been conducted. Based on its monoclonal antibody structure, it is not excreted renally or biliary unchanged. Elimination is primarily through intracellular catabolism, with no urinary or fecal excretion of intact drug.
Obinutuzumab binds specifically to CD20 antigen on B-cells; plasma protein binding is negligible (<1%) as it is a monoclonal antibody.
Ocrelizumab is a monoclonal antibody; typical Ig G binding to Fc Rn is p H-dependent, but standard protein binding experiments are not performed. It does not primarily bind to plasma proteins like albumin; thus, reported free fraction is >95% unbound, with minimal nonspecific binding.
The volume of distribution is approximately 3.8 L (0.05 L/kg for a 70 kg adult), reflecting limited extravascular distribution primarily to lymphoid tissues.
Volume of distribution is approximately 2.7 L (0.04 L/kg for a 70 kg patient), indicating limited extravascular distribution, consistent with a large monoclonal antibody primarily confined to plasma and interstitial space.
Obinutuzumab is only administered intravenously; oral bioavailability is 0%. Subcutaneous formulations are not available.
Subcutaneous: Bioavailability is approximately 50–60% (absolute bioavailability not determined; relative to IV, AUC is 65%). Not available for other routes.
No dose adjustment required for mild to moderate renal impairment (Cr Cl >=30 m L/min). Safety and efficacy not established in severe renal impairment (Cr Cl <30 m L/min).
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (GFR <30 m L/min) or end-stage renal disease.
No dose adjustment required for mild hepatic impairment (Child-Pugh A). Not recommended for moderate to severe hepatic impairment (Child-Pugh B or C).
No dose adjustment required for mild hepatic impairment (Child-Pugh A). Not studied in moderate or severe hepatic impairment (Child-Pugh B or C).
Safety and efficacy not established in pediatric patients.
Safety and efficacy not established in pediatric patients. No approved dosing.
No specific dose adjustment required; monitor for infusion-related reactions and hematologic toxicities more frequently.
No specific dose adjustment recommended for elderly patients. Clinical studies included patients up to age 65 with no dose modifications.
Hepatitis B virus reactivation, including fulminant hepatitis, hepatic failure, and death; Progressive multifocal leukoencephalopathy (PML) resulting in death.
WARNING: INFUSION-RELATED REACTIONS, HYPERSENSITIVITY, AND INCREASED RISK OF INFECTIONS. Infusion-related reactions can occur during or after infusion, including anaphylaxis, acute respiratory distress syndrome, urticaria, and hypotension. Hypersensitivity reactions, including anaphylaxis, have been reported. Ocrevus Zunovo increases the risk of upper respiratory tract infections, lower respiratory tract infections, and herpes infections. Patients should be monitored during infusion and for at least one hour post-infusion.
Infusion reactions (including severe and life-threatening reactions),Tumor lysis syndrome,Neutropenia and thrombocytopenia,Infections (including severe and opportunistic infections),Hepatitis B reactivation,Progressive multifocal leukoencephalopathy (PML),Immunization with live viral vaccines
Infusion reactions: premedicate with corticosteroids and antihistamines; monitor during infusion and for at least 1 hour after.,Infections: increased risk, especially upper and lower respiratory tract infections and herpes infections; delay administration in patients with active infection.,Hepatitis B virus reactivation: screen all patients for HBV; do not start in patients with active hepatitis.,Progressive multifocal leukoencephalopathy (PML): withhold if PML suspected; discontinue if confirmed.,Vaccination: administer all required vaccines at least 4 weeks prior to starting therapy; live vaccines not recommended during treatment.,Immunoglobulin levels: monitor; consider discontinuation if low.,Fetal harm: may cause fetal harm; advise effective contraception during and for 3 months after last infusion.
Known hypersensitivity to obinutuzumab or any excipient,Active hepatitis B infection
Active hepatitis B virus infection.,History of life-threatening infusion reaction to Ocrevus Zunovo.,Known active infections (e.g., tuberculosis, sepsis).,Severe immunocompromised state (e.g., current immunosuppressive therapy).
No known food interactions. Grapefruit and other CYP3A4 inhibitors are not expected to affect obinutuzumab as it is a monoclonal antibody cleared by non-renal, non-hepatic mechanisms.
No known food interactions. Ocrevus Zunovo may be administered without regard to meals.
First trimester: limited human data, but based on mechanism (anti-CD20 monoclonal antibody), potential B-cell depletion in fetus. Second/third trimesters: Ig G crosses placenta; fetal B-cell depletion and cytopenias possible. Avoid unless benefit outweighs risk.
Ocrelizumab (OCREVUS ZUNOVO) is a humanized anti-CD20 monoclonal antibody that crosses the placenta. In first trimester, B-cell depletion may occur; second and third trimester exposure is associated with fetal B-cell lymphocytopenia and potential increased infection risk. Animal studies show no direct teratogenicity, but human data are limited. Avoid during pregnancy unless benefit outweighs risk.
No data on presence in human milk; however, Ig G antibodies are excreted in breast milk. M/P ratio unknown. Discontinue breastfeeding or avoid drug due to potential for B-cell depletion in infant.
Ocrelizumab is excreted into human breast milk in low amounts (estimated M/P ratio not established; Ig G monoclonal antibodies have limited transfer). Preterm infants and neonates may have reduced absorption. Consider developmental benefits of breastfeeding, maternal need for therapy, and potential infant immunosuppression. Monitor infant for B-cell levels and infections.
No specific dose adjustments recommended; pharmacokinetics may be altered due to increased volume of distribution and clearance. Use standard dosing if clinically indicated, with careful monitoring of efficacy and toxicity.
No formal dosing adjustments for pregnancy. Pharmacokinetics may change due to increased plasma volume and altered clearance, but no well-controlled studies. Generally, maintain same dose; if severe infusion reaction risk, consider slower infusion rate or premedication. Postpartum, consider timing of next dose relative to breastfeedin if applicable.
Administer premedication (acetaminophen, antihistamine, corticosteroid) for infusion reactions. Monitor for tumor lysis syndrome (TLS) and provide prophylaxis (hydration, uric acid reducers) in high-risk patients. Do not administer live vaccines during treatment. Screen for hepatitis B virus (HBV) infection before initiation. Use in CLL patients with del(17p) or TP53 mutation is an NCCN category 1 recommendation.
Ocrevus Zunovo (ocrelizumab/hyaluronidase) is a subcutaneous formulation of ocrelizumab with recombinant human hyaluronidase to facilitate absorption. Administer subcutaneously in the abdomen over approximately 10 minutes. Premedicate with methylprednisolone (100 mg IV or equivalent oral) and an antihistamine (e.g., diphenhydramine 50 mg) approximately 30 minutes prior to each injection to reduce infusion reactions. Monitor for injection-site reactions, including erythema, pain, and swelling. Live-attenuated vaccines are contraindicated during treatment and until B-cell repletion. Do not administer if active infection is present.
You will receive premedication before each infusion to reduce infusion reactions.,Report any fever, chills, rash, or difficulty breathing during or after infusion immediately.,Do not receive live vaccines during treatment and for at least 6 months after last dose.,Your doctor will monitor for signs of tumor lysis syndrome (e.g., nausea, vomiting, muscle cramps, seizures).,You may be at increased risk of infections; report any signs of infection (fever, cough, sore throat).,This drug can lower blood counts; you may need regular blood tests.
Ocrevus Zunovo is given as a subcutaneous injection every 6 months after the initial two doses separated by 2 weeks.,You will receive premedication before each injection to reduce the risk of allergic reactions.,Common side effects include injection-site reactions, headache, and upper respiratory tract infections.,Avoid live vaccines (e.g., MMR, varicella, intranasal flu) during treatment and for at least 4 weeks before starting.,Contact your healthcare provider immediately if you develop symptoms of infection, such as fever, chills, or cough.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about GAZYVA vs OCREVUS ZUNOVO, answered by our medical review team.
GAZYVA is a CD20-directed Monoclonal Antibody that works by Obinutuzumab is a type II anti-CD20 monoclonal antibody that binds to the CD20 antigen on B cells, inducing direct cell death, antibody-dependent cellular cytotoxicity, and antibody-dependent cellular phagocytosis.. OCREVUS ZUNOVO is a CD20-directed monoclonal antibody that works by OCREVUS ZUNOVO is a recombinant humanized monoclonal antibody that targets CD20-positive B cells. It binds to the CD20 antigen on the surface of pre-B and mature B lymphocytes, leading to antibody-dependent cellular cytotoxicity and complement-mediated lysis, resulting in B-cell depletion.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between GAZYVA and OCREVUS ZUNOVO depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of GAZYVA is: 100 mg intravenously on day 1, 8, 15 of cycle 1, then 100 mg on day 1 of subsequent 28-day cycles for 6 cycles total.. The standard adult dose of OCREVUS ZUNOVO is: Initial dose: 300 mg intravenous infusion over 4 hours followed 2 weeks later by a second 300 mg intravenous infusion over 4 hours. Subsequent doses: 600 mg intravenous infusion over 3.5 hours every 6 months.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between GAZYVA and OCREVUS ZUNOVO in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. GAZYVA is classified as Category C. First trimester: limited human data, but based on mechanism (anti-CD20 monoclonal antibody), potential B-cell depletion in fetus. Second/third trimesters: IgG crosses placenta; fet. OCREVUS ZUNOVO is classified as Category C. Ocrelizumab (OCREVUS ZUNOVO) is a humanized anti-CD20 monoclonal antibody that crosses the placenta. In first trimester, B-cell depletion may occur; second and third trimester expo. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.